EFFICACY AND SAFETY OF MODERN MINIMALLY INVASIVE GLAUCOMA SURGERY - AB INTERNO CANALOPLASTY - IN 18 MONTHS OF FOLLOW-UP (OWN EXPERIENCE).
Published 2024 - 28th ESCRS Winter Meeting
Reference: P179 | Type: Submission | DOI: 10.82333/3ad8-ct52
Authors: Wojciech Maruszczyk* 1 , Łukasz Drzyzga 1 , Dominik Dygas 1 , Michał Bogocz 2 , Marta Świerczyńska 2 , Katarzyna Gontarz 2 , Michalina Gałuszka 2 , Aleksandra Bukowska 2 , Mariola Dorecka 2 , Ewa Mrukwa-Kominek 2 , Dorota Wyględowska-Promieńska 2
1Department of Ophthalmology,Prof. K. Gibinski University Clinical Center, Medical University of Silesia in Katowice,Katowice,Poland, 2Department of Ophthalmology,Prof. K. Gibinski University Clinical Center, Medical University of Silesia in Katowice,Katowice,Poland;Department of Ophthalmology,Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice,Katowice,Poland
Purpose
Canaloplasty is one of the minimally invasive surgical glaucoma treatment method. There are many modifications, including the ab interno and ab externo access. The procedure purpose is to improve the natural outflow of aqueous humor through the Schlemm's canal. After intervention hypotony can be avoided since aqueous is allowed to drain via the physiological outflow system. The aim of the study is to evaluate the efficacy and safety of ABiC for the treatment of open angle glaucoma in various patients in 18 month follow-up period.
Setting
Department of Ophthalmology, Prof. K. Gibinski University Clinical Centre, Medical University of Silesia in Katowice, Katowice – Poland
Methods
Patients with diagnosed glaucoma and insufficiently regulated intraocular pressure despite maximally tolerable antiglaucoma medications were selected to the study. We included 51 adult patients with various open angle glaucoma subtypes. All of them underwent ABiC procedure between 2017 to 2021 and had at least 18-months of follow-up period. Patients were treated with the modern ab-interno surgical technique using the iTrack canaloplasty microcatheter (Nova Eye Medical). Patients with 360-degree successful catheterization only were selected for this study. After the procedure we assessed the post-operative intraocular pressure, best corrected visual acuity, the number of adverse events and complications and the number of antiglaucoma medications. The follow-up will be continued.
Results
After the procedure the mean intraocular pressure reduction and stabilisation was observed. The mean IOP was 25,21±9,05mmHg, 17,05±7,37 mmHg, 17,18±2,79 mmHg, 17,57±1,71 mmHg, 16,5±1,69 mmHg, 14,5±5,05 and 14,42±4,96 mmHg before, 1 day, 1, 3, 6, 12, 18 months after the surgery, respectively. The mean usage of the anti-glaucoma topical medications was 2,9±1,02, 1,55±1,39, 2,1±0,74, 2,17±0,75, 2,0±1,2, 2,14±1,07 and 2,08±1,16, before, 1 day, 1, 3, 6, 12 and 18 months after the surgery, respectively. No decrease in BCVA and no severe complications were observed. Some of the patients after the surgery were qualified for another antiglaucoma surgery due to insufficient intraocular pressure reduction.
Conclusion
Ab-interno canaloplasty appears to be a safe and effective treatment for glaucoma in all stages of the disease, although further studies are required to assess the long-term effect and late postoperative complication rate.